Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 DDI Study of DS-3201b With Itraconazole and Fluconazole in Healthy Japanese Subjects
jRCT2080223846Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucidinostat in Neoplasm (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Effect of itraconazole on DS-3201a pharmacokinetics and Effect of fluconazole on DS-3201a pharmacokinetics.
02
Drugs
tucidinostat
03
Conditions
Neoplasm
Beyond the preview
Go deeper on jRCT2080223846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223846.